海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Study to test the safety, tolerability, and effectiveness of sitagliptin when compared to placebo in reducing the amount of insulin (with or without metformin) needed per day, to control blood sugar, over a 24-week period.
- Type 2 Diabetes Mellitus MedDRA version: 14.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Australia, Belgium, Brazil, Canada, Denmark, France, Germany, Hungary, India, Ireland, Israel, Italy, Korea, Democratic People's Republic of, Lithuania, Mexico, New Zealand, Norway, Peru, Poland, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Turkey, United Kingdom, United States
- 2011-10-18
Authorised
- Clinical study in which patients with bone cancer in the leg and who are undergoing surgery to remove the tumor and reconstruct the leg using a metal implant are randomly assigned to 1 of 2 antibiotic regimens.
- * Patients with a primary bone malignancy or soft-tissue sarcoma that has invaded a lower extremity bone that are undergoing surgical treatment to resect the tumor and functionally reconstruct the limb using a modular metallic and polyethylene endoprosthetic implant to replace the surgically resected bones and joints. * Development of a surgical site infection according to the guidelines established by the Centers for Disease Control and Prevention (CDC) MedDRA version: 20.0 Level: PT Classification code 10064736 Term: Antibiotic prophylaxis System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 20.1 Level: LLT Classification code 10056641 Term: Post procedural site wound infection System Organ Class: 100000004862 MedDRA version: 20.1 Level: PT Classification code 10068943 Term: Limb reconstructive surgery System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 20.0 Level: LLT Classification code 10036894 Term: Prophylactic antibiotic therapy System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 20.0 Level: PT Classification code 10005978 Term: Bone lesion excision System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 20.0 Level: PT Classification code 10073235 Term: Bone prosthesis insertion System Organ Class: 10042613 - Surgical and medical procedures MedDRA version: 20.0 Level: PT Classification code 10006007 Term: Bone sarcoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Argentina, Australia, Austria, Brazil, Canada, South Africa, Spain, United States
- 2017-09-07
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn's Disease (AIDA)
- Ulcerative colitis or Crohn's Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2017-09-04
Authorised
- This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy, tolerability and safety of pulsed inhaled nitric oxide 75mcg/kg IBW/hr, 12 hours per day or longer for 18 weeks in symptomatic subjects with pulmonary arterial hypertension. (Part 1), followed by an open-label extension (Part 2) which provides active therapy to all subjects completing the first 18 weeks.
- Pulmonary Arterial Hypertension MedDRA version: 20.0 Level: PT Classification code 10064911 Term: Pulmonary arterial hypertension System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Australia, Austria, Belgium, Canada, Colombia, Croatia, Czech Republic, France, Germany, Hungary, Israel, Italy, Korea, Republic of, Netherlands, Portugal, Serbia, Spain, Ukraine, United Kingdom, United States
- 2016-04-11
Authorised
- Estudio de fase II, aleatorizado, abierto, multicéntrico, para evaluar la eficacia de sorafenib solo y sorafenib en combinación con interferón alfa-2a a dosis bajas como tratamiento de segunda línea tras el fracaso a sunitinib en pacientes con carcinoma metastásico de células renales (CCR) (A Phase II, Randomized, Open-label, MultiCenter, Study Evaluating the Efficacy of SOrafenib AloNe and Sorafenib in Combination with Low DosE InterfeRon Alpha-2a as Second-line Treatment of Sunitinib Failure in Patients with Metastatic Renal Cell Carcinoma (RCC)) - CONCERT
- Carcinoma metastásico de células renales (Advanced renal cell cancer.) MedDRA version: 9.1 Level: LLT Classification code 10038407 Term: Renal cell cancer
- Austria, France, Ireland, Italy, Poland, Spain, United Kingdom
- 2007-12-28
Authorised
- A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancer
- Extensive Stage Disease Small Cell Lung Cancer (ED SCLC) MedDRA version: 17.0 Level: PT Classification code 10041068 Term: Small cell lung cancer extensive stage System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belarus, Canada, Korea, Democratic People's Republic of, Netherlands, New Zealand, Puerto Rico, Russian Federation, Spain, Taiwan, United States
- 2014-09-22
Authorised
- A multicentre and international trial of a new treatment regimen containing paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for people with chronic hepatitis C virus genotype 1 infection and recent injection drug use or receiving opioid substitution therapy.
- Chronic hepatitis C virus genotype 1 infection MedDRA version: 19.0 Level: LLT Classification code 10072844 Term: Hepatitis C virus genotype 1a positive System Organ Class: 100000004848 MedDRA version: 19.0 Level: LLT Classification code 10072845 Term: Hepatitis C virus genotype 1b positive System Organ Class: 100000004848 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Canada, France, New Zealand, Norway, Switzerland
- 2016-07-08
Authorised
- A clinical study performed at several sites with a treatment duration of 6 months, with 3 treatment arms (2 different dosages LM11A-31-BHS and 1 placebo), which are randomly distributed in a double-blind manner (neither physician nor patient will know which treatment arm) between the patients to evaluate safety, tolerability and other questions of research of the two different oral dosages of LM11A-31-BHS in comparison with placebo in patients with mild to moderate probable Alzheimer’s disease
- Mild to moderate Alzheimer's disease MedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 MedDRA version: 19.0 Level: LLT Classification code 10066571 Term: Progression of Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria
- 2016-05-25
Authorised
- Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) versus Anti-Thyroid Drugs (ATD) in Patients with Moderate-to-Severe Graves’ Ophthalmopathy - a 1-year Follow-up
- Graves' disease, hyperthyroidism;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Austria
- 2015-09-30
Authorised
- Research study to determine whether an investigational drug, SHP647, is safe and effective long term in the treatment of moderate to severe Ulcerative Colitis or Crohn's Disease (AIDA)
- Ulcerative colitis or Crohn's Disease MedDRA version: 20.1 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2017-10-25